Overview
Leukemia — cancer of the blood and bone marrow — encompasses a spectrum of diseases ranging from highly curable acute leukemias to chronic conditions requiring long-term management. For patients with high-risk or relapsed leukemia, hematopoietic stem cell transplantation (HSCT) remains the most powerful curative option — and the expertise of the transplant team is the single most important determinant of outcome. Shanghai is home to one of China's most experienced leukemia and transplantation programs, led by a specialist who has dedicated his career to advancing both the clinical and scientific frontiers of this field.
China Medical Concierge Shanghai (CMCS) connects international patients with Shanghai's top hematology specialists, providing end-to-end support from remote consultation through to post-treatment follow-up.
Understanding Leukemia
Types of Leukemia
Leukemia is broadly classified by the speed of progression (acute vs. chronic) and the type of blood cell affected (myeloid vs. lymphoid):
- Acute myeloid leukemia (AML) — the most common acute leukemia in adults; requires urgent treatment; prognosis depends heavily on cytogenetic and molecular risk stratification
- Acute lymphoblastic leukemia (ALL) — the most common leukemia in children; also occurs in adults; Philadelphia chromosome-positive ALL requires targeted therapy with TKIs
- Chronic myeloid leukemia (CML) — driven by the BCR-ABL fusion gene; highly responsive to tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, ponatinib)
- Chronic lymphocytic leukemia (CLL) — the most common leukemia in Western adults; managed with BTK inhibitors, BCL2 inhibitors, and anti-CD20 antibodies
- Myelodysplastic syndromes (MDS) — pre-leukemic conditions with risk of transformation to AML; HSCT is the only curative option for high-risk MDS
Common Symptoms
- Fatigue, pallor, and shortness of breath (anaemia)
- Recurrent infections (neutropenia)
- Easy bruising or bleeding (thrombocytopenia)
- Bone pain and joint pain
- Swollen lymph nodes, spleen, or liver
- Unexplained fever and night sweats
- Unexplained weight loss
Diagnosis & Risk Stratification
- Complete blood count (CBC) and peripheral blood smear — initial assessment
- Bone marrow biopsy and aspiration — definitive diagnosis and blast percentage
- Cytogenetics (karyotype and FISH) — chromosomal abnormalities for risk stratification
- Molecular profiling (NGS) — FLT3, NPM1, IDH1/2, CEBPA, TP53, RUNX1 for AML; BCR-ABL for CML/ALL; IGHV, TP53, del(17p) for CLL
- Immunophenotyping (flow cytometry) — cell surface marker characterization
- Minimal residual disease (MRD) monitoring — treatment response assessment and relapse prediction
Treatment: Leukemia & Hematopoietic Stem Cell Transplantation
Acute Myeloid Leukemia (AML)
- Induction chemotherapy — "7+3" (cytarabine + anthracycline) or targeted induction for FLT3-mutant (midostaurin) or IDH1/2-mutant AML (ivosidenib, enasidenib)
- Consolidation — high-dose cytarabine or HSCT for high-risk disease
- Relapsed/refractory AML — venetoclax combinations, gilteritinib (FLT3), enasidenib (IDH2), glasdegib, and clinical trials
Acute Lymphoblastic Leukemia (ALL)
- Induction, consolidation, and maintenance — multi-agent chemotherapy protocols
- Ph+ ALL — TKI (ponatinib, dasatinib) combined with chemotherapy or blinatumomab
- Blinatumomab — bispecific T-cell engager for relapsed/refractory B-ALL
- CAR-T therapy — tisagenlecleucel for relapsed/refractory B-ALL
Hematopoietic Stem Cell Transplantation (HSCT)
HSCT is the most powerful curative treatment for high-risk leukemia and MDS. It involves replacing the patient's diseased bone marrow with healthy stem cells from a donor (allogeneic HSCT) or from the patient themselves after high-dose chemotherapy (autologous HSCT).
Key aspects of HSCT include:
- Donor selection — matched sibling donor (MSD), matched unrelated donor (MUD), haploidentical (half-matched) donor, or umbilical cord blood
- Conditioning regimen — myeloablative or reduced-intensity conditioning based on patient age and fitness
- Graft-versus-host disease (GvHD) prevention and management — a critical determinant of transplant outcome
- Graft-versus-leukemia (GvL) effect — the immune mechanism by which allogeneic HSCT eradicates residual leukemia
- Post-transplant MRD monitoring — early detection of relapse and pre-emptive intervention
Haploidentical Transplantation
For patients without a matched sibling or unrelated donor, haploidentical (half-matched) transplantation — using a parent, child, or sibling as donor — has become an increasingly effective alternative, with outcomes approaching those of matched donor transplants at experienced centers. China has been a global leader in the development of haploidentical transplantation protocols.
Why Choose Changhai Hospital for Leukemia & Transplantation?
- China's premier military medical university hospital — Changhai Hospital (Naval Medical University) is one of China's most prestigious academic medical centers
- National leadership in leukemia and HSCT — Prof. Wang's Institute of Hematology is a national center of excellence for leukemia treatment and transplantation research
- Extensive haploidentical transplantation experience — a critical capability for patients without matched donors
- Comprehensive molecular risk stratification — full NGS-based profiling to guide treatment selection and transplant timing
- Cost-effective world-class care — significantly lower cost than equivalent treatment in the US, UK, or Singapore
Featured Specialist: Prof. Wang Jianmin — Changhai Hospital, Naval Medical University
Prof. Wang Jianmin (王健民) is a Professor of Hematology and Director of the Institute of Hematology, People's Liberation Army (PLA) at Changhai Hospital, Naval Medical University — one of China's most prestigious military academic medical centers. He has served as Vice Chairman of the Hematology Branch of the Chinese Medical Association and Chairman of the Shanghai Medical Association Hematology Branch — two of the most senior positions in Chinese hematology.
National Authority in Leukemia & Transplantation
Prof. Wang has dedicated his career to advancing the clinical and scientific frontiers of leukemia treatment and hematopoietic stem cell transplantation. His long-term focus on both the clinical management of leukemia and the basic science of HSCT — including GvHD biology, GvL mechanisms, and post-transplant immune reconstitution — has established him as one of China's most respected authorities in this field.
Clinical Expertise
- Acute myeloid leukemia (AML) — risk-stratified treatment including targeted therapy and HSCT
- Acute lymphoblastic leukemia (ALL) — including Ph+ ALL and relapsed/refractory disease
- Chronic myeloid leukemia (CML) — TKI therapy and transplantation for advanced-phase disease
- Myelodysplastic syndromes (MDS) — risk stratification and HSCT for high-risk disease
- Allogeneic HSCT — matched sibling, matched unrelated, and haploidentical transplantation
- GvHD prevention and management — a critical determinant of transplant outcome
- Post-transplant MRD monitoring and relapse management
For international patients, Prof. Wang's team offers remote pre-consultation review of bone marrow biopsy, cytogenetics, molecular profiling, and prior treatment records, enabling a precise risk assessment and treatment recommendation to be developed before arrival in Shanghai.
How CMCS Supports Your Journey
CMCS is not a hospital — we are your dedicated medical concierge, providing a trusted bridge between international patients and Shanghai's finest cancer specialists.
Our services include:
- ✅ Direct appointment coordination with Prof. Wang Jianmin and the Changhai Hospital hematology team
- ✅ Bone marrow biopsy, cytogenetics, molecular profiling, and prior treatment record translation and pre-consultation review
- ✅ HSCT eligibility and donor matching assessment coordination
- ✅ Second opinion facilitation
- ✅ Hospital admission and treatment scheduling support
- ✅ Accommodation and logistics coordination in Shanghai
- ✅ Post-treatment follow-up and remote check-in support
Contact CMCS
If you or a loved one has been diagnosed with leukemia or requires stem cell transplantation assessment, our team is ready to help.
📧 Email: contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 Website: www.medicalsh.com
CMCS — China Medical Concierge Shanghai. Connecting international patients with Shanghai's finest specialists.
0件のコメント